Limits...
Effect of Bevacizumab on Human Tenon's Fibroblasts Cultured from Primary and Recurrent Pterygium.

Park YM, Kim CD, Lee JS - Korean J. Physiol. Pharmacol. (2015)

Bottom Line: Both types of HTFs had significant decreases in MMP-1, PIP, and laminin levels.Significant changes in cellular density and morphology both occurred at bevacizumab concentrations greater than 7.5 mg/mL.As the primary HTFs produces larger amounts of MMP-1 compared to recurrent HTFs, significant reduction in MMP-1 level in primary pterygium HTFs after exposure to bevacizumab is likely to be related to the faster cellular density changes in primary pterygium HTFs.

View Article: PubMed Central - PubMed

Affiliation: Department of Ophthalmology, Pusan National University School of Medicine & Medical Research Institute, Yangsan Pusan National University Hospital, Yangsan 626-770, Korea.

ABSTRACT
The purpose of this study was to compare the inhibitory effect of bevacizumab on human Tenon's fibroblasts (HTFs) cultured from primary and recurrent pterygium. Cultured HTFs were exposed to 2.0, 5.0, 7.5, and 15.0 mg/mL concentration of bevacizumab for 24 hours. The 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyl tetrazolium bromide and lactate dehydrogenase leakage assays were then performed to assess fibroblast metabolism and viability. The matrix metalloproteinase (MMP), procollagen type I C terminal propeptide (PIP), and laminin immunoassays were performed to examine extracellular matrix production. Changes in cellular morphology were examined by phase-contrast and transmission electron microscopy. Both metabolic activity and viability of primary and recurrent pterygium HTFs were inhibited by bevacizumab in a dose-dependent manner, especially at concentrations greater than 7.5 mg/mL. Both types of HTFs had significant decreases in MMP-1, PIP, and laminin levels. Distinctly, the inhibitory effect of bevacizumab on MMP-1 level related with collagenase in primary pterygium HTFs was significantly higher than that of recurrent pterygium. Significant changes in cellular density and morphology both occurred at bevacizumab concentrations greater than 7.5 mg/mL. Only primary pterygium HTFs had a reduction in cellular density at a bevacizumab concentration of 5.0 mg/mL. Bevacizumab inhibits primary and recurrent pterygium HTFs in a dose-dependent manner, especially at concentrations greater than 7.5 mg/mL. As the primary HTFs produces larger amounts of MMP-1 compared to recurrent HTFs, significant reduction in MMP-1 level in primary pterygium HTFs after exposure to bevacizumab is likely to be related to the faster cellular density changes in primary pterygium HTFs.

No MeSH data available.


Related in: MedlinePlus

Effect of bevacizumab concentration on primary and recurrent pterygium human Tenon's fibroblast morphology (inverted phase-light microscopy and TEM images).
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4499648&req=5

Figure 5: Effect of bevacizumab concentration on primary and recurrent pterygium human Tenon's fibroblast morphology (inverted phase-light microscopy and TEM images).

Mentions: Before the bevacizumab application, inverted phase-light microscopy showed that HTFs were uniform and densely distributed in the culture medium. After 24 hours exposure to 2.0 mg/mL concentration of bevacizumab, primary and recurrent pterygium HTFs had similar culture densities as that of control HTFs. When HTFs were exposed to bevacizumab concentrations greater than 7.5 mg/mL, a significant reduction in cellular density was observed and significant morphological changes developed. Interestingly, only primary pterygium HTFs had a reduction in cellular density at a bevacizumab concentration of 5.0 mg/mL. Significant changes in cellular density and morphology both occurred at bevacizumab concentrations greater than 7.5 mg/mL (Fig. 5).


Effect of Bevacizumab on Human Tenon's Fibroblasts Cultured from Primary and Recurrent Pterygium.

Park YM, Kim CD, Lee JS - Korean J. Physiol. Pharmacol. (2015)

Effect of bevacizumab concentration on primary and recurrent pterygium human Tenon's fibroblast morphology (inverted phase-light microscopy and TEM images).
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4499648&req=5

Figure 5: Effect of bevacizumab concentration on primary and recurrent pterygium human Tenon's fibroblast morphology (inverted phase-light microscopy and TEM images).
Mentions: Before the bevacizumab application, inverted phase-light microscopy showed that HTFs were uniform and densely distributed in the culture medium. After 24 hours exposure to 2.0 mg/mL concentration of bevacizumab, primary and recurrent pterygium HTFs had similar culture densities as that of control HTFs. When HTFs were exposed to bevacizumab concentrations greater than 7.5 mg/mL, a significant reduction in cellular density was observed and significant morphological changes developed. Interestingly, only primary pterygium HTFs had a reduction in cellular density at a bevacizumab concentration of 5.0 mg/mL. Significant changes in cellular density and morphology both occurred at bevacizumab concentrations greater than 7.5 mg/mL (Fig. 5).

Bottom Line: Both types of HTFs had significant decreases in MMP-1, PIP, and laminin levels.Significant changes in cellular density and morphology both occurred at bevacizumab concentrations greater than 7.5 mg/mL.As the primary HTFs produces larger amounts of MMP-1 compared to recurrent HTFs, significant reduction in MMP-1 level in primary pterygium HTFs after exposure to bevacizumab is likely to be related to the faster cellular density changes in primary pterygium HTFs.

View Article: PubMed Central - PubMed

Affiliation: Department of Ophthalmology, Pusan National University School of Medicine & Medical Research Institute, Yangsan Pusan National University Hospital, Yangsan 626-770, Korea.

ABSTRACT
The purpose of this study was to compare the inhibitory effect of bevacizumab on human Tenon's fibroblasts (HTFs) cultured from primary and recurrent pterygium. Cultured HTFs were exposed to 2.0, 5.0, 7.5, and 15.0 mg/mL concentration of bevacizumab for 24 hours. The 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyl tetrazolium bromide and lactate dehydrogenase leakage assays were then performed to assess fibroblast metabolism and viability. The matrix metalloproteinase (MMP), procollagen type I C terminal propeptide (PIP), and laminin immunoassays were performed to examine extracellular matrix production. Changes in cellular morphology were examined by phase-contrast and transmission electron microscopy. Both metabolic activity and viability of primary and recurrent pterygium HTFs were inhibited by bevacizumab in a dose-dependent manner, especially at concentrations greater than 7.5 mg/mL. Both types of HTFs had significant decreases in MMP-1, PIP, and laminin levels. Distinctly, the inhibitory effect of bevacizumab on MMP-1 level related with collagenase in primary pterygium HTFs was significantly higher than that of recurrent pterygium. Significant changes in cellular density and morphology both occurred at bevacizumab concentrations greater than 7.5 mg/mL. Only primary pterygium HTFs had a reduction in cellular density at a bevacizumab concentration of 5.0 mg/mL. Bevacizumab inhibits primary and recurrent pterygium HTFs in a dose-dependent manner, especially at concentrations greater than 7.5 mg/mL. As the primary HTFs produces larger amounts of MMP-1 compared to recurrent HTFs, significant reduction in MMP-1 level in primary pterygium HTFs after exposure to bevacizumab is likely to be related to the faster cellular density changes in primary pterygium HTFs.

No MeSH data available.


Related in: MedlinePlus